Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) WilsonEncourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options
If you suffered significant losses inPliant Therapeutics stock or options and would like to discuss your legal rights,call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330(Ext. 1310).
[You may also click here for additional information]
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pliant Therapeutics, Inc. (“Pliant” or the “Company”) (NASDAQ: PLRX).
https://mma.prnewswire.com/media/2457438/Faruqi_Logo.jpg
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
OnFebruary 7, 2025, Pliant issued a press release “announc[ing] that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase2btrial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).” Following this news, Wells Fargo and Citi analysts both downgraded Pliant, citing uncertainty about bexotegrast's path forward.
On this news, Pliant's stock price fell$4.72per share, or 60.59%, to close at$3.07per share onFebruary 10, 2025.
To learn more about the Pliant Therapeutics investigation, go to www.faruqilaw.com/PLRX or callFaruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330(Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
https://mma.prnewswire.com/media/1959220/Logo_11_30_2022.jpg
https://c212.net/c/img/favicon.png?sn=NY51944&sd=2025-03-28
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-faruqi–faruqi-llp-investigates-claims-on-behalf-of-investors-of-pliant-therapeutics-302413609.html
SOURCE Faruqi & Faruqi, LLP
https://rt.newswire.ca/rt.gif?NewsItemId=NY51944&Transmission_Id=202503280959PR_NEWS_USPR_____NY51944&DateId=20250328